Loading Alkem Laboratories…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 3,740 | 3,603 | 3,737 | 4,001 | 3,371 |
| Operating profit | 666 | 412 | 733 | 827 | 651 |
| Operating margin | 17.8% | 11.4% | 19.6% | 20.7% | 19.3% |
| Net profit | 520 | 236 | 636 | 765 | 664 |
| Net margin | 13.9% | 6.6% | 17.0% | 19.1% | 19.7% |
| EPS (₹) | 43.49 | 19.77 | 53.19 | 63.99 | 55.56 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 14,532 | 12,805 | 12,439 | 11,440 |
| Operating profit | 2,649 | 2,184 | 1,985 | 1,334 |
| Operating margin | 18.2% | 17.1% | 16.0% | 11.7% |
| Net profit | 2,302 | 2,165 | 1,796 | 984 |
| Net margin | 15.8% | 16.9% | 14.4% | 8.6% |
| EPS (₹) | 192.51 | 181.11 | 150.19 | 82.31 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 20,873 | 17,691 | 15,575 | 13,757 |
| Total liabilities | 6,524 | 5,257 | 4,861 | 4,322 |
| Shareholders’ equity | 13,820 | 11,985 | 10,312 | 9,045 |
| Total debt | 2,047 | 1,381 | 1,418 | 1,397 |
| Cash & equivalents | 248 | 304 | 455 | 274 |
| Debt / equity | 0.15 | 0.12 | 0.14 | 0.15 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 1,963 | 1,913 | 1,948 | 1,683 |
| Capital expenditure | -617 | -676 | -259 | -233 |
| Free cash flow | 1,346 | 1,237 | 1,689 | 1,450 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 16.7% | 18.1% | 17.4% | 10.9% |
| Return on assets | 11.0% | 12.2% | 11.5% | 7.2% |
| Net margin | 15.8% | 16.9% | 14.4% | 8.6% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for ALKEM. Finnhub coverage is limited for some India-listed stocks.